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The potential for divergent biology from
one tumor-derived GIC/GSC population
to another has profound therapeutic impli-
cations. For example, it was demonstrated
that BMP2/4 induces terminal differentia-
tion in GICs/GSCs, leading to the sugges-
tion that BMP2/4 and/or their agonist
might represent a therapeutic strategy for
gliomas (Piccirillo et al., 2006).WhenGICs/
GSCs froma larger set ofGBMswere eval-
uated, however, it was found that about
20% of GBMs harbor GICs/GSCs with ab-
errant methylation of the BMP receptor 1b
(BMPR1b) promoter converting BMP2/4
from a differentiation agent to a mitogenic
agent (Lee et al., 2008). Thus, not only
would a BMP2/4 agonist fail as a thera-
peutic strategy in these tumors, it might
actually promote GIC/GSC expansion
and tumor growth. In fact, these same
BMPR1b-methylated GICs/GSCs are LIF
unresponsive secondary to the failure of
LIF to induce phosphorylation of STAT3 in
these cells. These GICs/GSCs (and their
parental tumors) are therefore likely to be
refractory to TGF-b and thus are unlikely
to benefit from therapeutic inhibition of
TGF-b and/or the JAK-STAT pathway.
Indeed, in thecontextofaveryearly embry-
onic NSC phenotype, STAT3 inhibition is
required for cells to exit symmetric cell divi-
sion and terminally differentiate. Thus, any
therapeutic strategy aimed at blocking the
JAK-STAT pathway in GICs/GSCs derived
from, or with a phenotype similar to, a very
early NSC could actually cause expansion
of the GIC/GSC pool.
Targeting stem cell pathways may ulti-
mately prove to be an effective therapeutic
strategy against malignant gliomas;
however, such pathways may have
dramatically divergent roles in GIC/GSC
populations from different GBMs. Thus,
regardless of whether GICs/GSCs come
from a true NSC or from the dedifferentia-
tion of a mature somatic cell (e.g., astro-
cyte), understanding the divergent sig-
naling mechanisms and phenotypes of
developmentally and anatomically speci-
fied normal NSCs will be vital for under-
standing the unique biology of GIC/GSC
populations from different malignant
tumors (Figure 1). Once those pathways
have been elucidated and validated as
potentially useful therapeutic targets, we
will ultimately need to identify easily as-
sessed surrogate molecular markers of
stem cell pathway activation within each
specific tumor (e.g., BMPR1b, TGF-b/LIF
expression) ifwewant to use such informa-
tion to guide therapeutic decision-making
for individual patients. The promise of
patient-specific stem cell pathway thera-
peutic targeting will therefore be best real-
ized through an ever greater collaborative
effort between neuroscientists, develop-
mental biologists, cancer researchers,
and clinical scientists.
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Properly designed genome-wide screening strategies can provide new insights into biological processes
and/or biomarkers for malignant diseases. In this issue of Cancer Cell, Huang et al. demonstrate that the
Kru¨ppel zinc-finger protein ZNF423 is critical for retinoic acid signaling and is likely a favorable prognostic
marker for neuroblastoma.Vitamin A is essential for development and
homeostasis in all vertebrate organisms.
All-trans retinoic acid (all-trans RA) isa key biologically active derivative of
vitamin A that can be isomerized into
9-cisRAand13-cisRA forms (compoundsCancer Cecollectively known as retinoids). The
biological actions of both natural and
synthetic retinoids are mediated viall 15, April 7, 2009 ª2009 Elsevier Inc. 249
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Previewsretinoic acid receptors (RARs). As
members of the nuclear receptor family,
RARs act as ligand-regulated transcrip-
tion factors directly or indirectly to modu-
late the expression of complex gene
networks. RARs function as heterodimers
formed from one of three RARs and one of
three retinoid X, or rexinoid, receptors
(RXRs). In the absence of agonists, RAR/
RXR heterodimers bind to some target
genes as corepressor complexes and
silence their transcription by histone
modification. The binding of an agonist250 Cancer Cell 15, April 7, 2009 ª2009 Elsereplaces corepressors with coactivators
within the RAR/RXR complex, thus
leading to initiation of transcription
through establishment of positively acting
chromatin modifications and interactions
with the basic transcriptional machinery.
Besides this relatively well-characterized
general mechanism of coregulator
exchange in modulating the activities of
nuclear receptors, the function of RARs
is regulated by additional cell/promoter
context-specific factors. These RA sig-
naling modulators (RAMs) exert diversevier Inc.but highly efficient effects onRA signaling.
For example, RAM has been shown to be
silenced by RA in the myelomonocytic
lineage, and its continuous expression
can confer resistance to RA-induced
differentiation and apoptosis (Yin et al.,
2006). Interestingly, RAM is unlikely to
encode a protein. PRAME is another
negatively acting RAM that binds RAR
and blocks its agonist-induced activation,
possibly by recruitment of the polycomb
PRC2 complex (Epping et al., 2005)
(Figure 1A).
Figure 1. Modulators of Retinoic Acid
Signaling
(A) Schematic representation of the role of ZNF423
in retinoic acid signaling and neuroblastoma differ-
entiation. Retinoic acid acts via the RXR/RAR het-
erodimeric complex (center) to induce neuroblas-
toma cells (bottom) to undergo differentiation
(top). ZNF423 can interact with RXR/RAR and stim-
ulate their transcriptional activities as well as the
differentiation of neuroblastoma cells. PRAME
represses RAR-mediated gene transcription
through recruitment of the PRC2-associated
EZH2 histone methyltransferase. Whether
ZNF423 competes with PRAME for RAR binding
or recruits positively acting epigenetic factors in
this cell-type context remains to be established.
(B) Schematic representation of the predicted 50
gene structure of ZNF423, Zfp423, and ZNF521.
Bioinformatic analysis (courtesy of Kevin Petrie)
suggests that ZNF423may be alternatively spliced
as well as being transcribed from two distinct puta-
tive promoters. In analogy with Zfp423, ZNF423
shares an N-terminal NuRD interaction domain
(NID), with the sequence MSRRKQAKPRSVK
(related or identical sequences in different proteins
are highlighted with the same colors), with several
other zinc-finger transcription factors (Bond et al.,
2008). ZNF423 also shares a high degree of overall
homology with ZNF521: although the N-terminal
regions of these two proteins are less homologous,
the NID is conserved. Mouse Zfp423 exon 0 is
drawn in dashed outline to indicate that although
mRNA corresponding to this exon has not been de-
tected, a sequence homologous to human ZNF423
exon 0 is present in the Zfp423 locus. Accession
numbers of mRNA sequences used for the above
analysis were taken from the NCBI Entrez Nucleo-
tide database: ZNF423, NM_015069, BX403293,
DB298660; Zfp423, NM_033327; ZNF521,
NM_015461.
(C) ZNF423 and ZNF521 are structurally highly
related, comprising an N-terminal NID (red bar)
and discrete clusters made up of 30 and 29 Kru¨p-
pel-like C2H2 zinc fingers (ZF, indicated by vertical
bars), respectively. A schematic representation of
the full-length NID-containing isoform of ZNF423
is shown, with the ZF clusters highlighted by
different colors (ZF 2–8, which bind DNA, can be
viewed as one or two clusters). Functional proper-
ties of other ZF modules are indicated below the
diagram as described previously (see Hata et al.,
2000). Identities/similarities between the corre-
sponding clusters of ZNF423 and ZNF521 are indi-
cated as percentage values above the diagram.
The two vertical dark gray bars represent an
N-terminal atypical ZF not present in ZNF521 and
a poorly conserved ZF that does not form part of
the C-terminal cluster.
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a large-scale RNA interference-based
genetic screen, Rene´ Bernards and
colleagues identify the zinc-finger protein
ZNF423 as a positively acting RAM
(Huang et al., 2009). Furthermore, they
show that ZNF423 can interact with all
RAR subtypes as well as RXR and is
required, at least in some cells, for effec-
tive transcriptional activation induced by
RA. In contrast to PRAME, the binding of
ZNF423 to RARs and RXRs does not
require ligand. However, the mechanistic
basis explaining why ZNF423 is critical
for RAR/RXR signaling remains unclear
(Figure 1A). Future studies will have
to address whether ZNF423 can bind
together with RAR/RXR to particular
composite DNAelements, has the proper-
ties of a coactivator, facilitates core-
pressor release, and/or recruits additional
factors. In this context, it is interesting to
note that (1) ZNF423 acts as a BMP4-
induced coregulator of the Smad1/4
complex (Ku et al., 2006) and (2) the DNA
binding and protein interaction domains
of ZNF423 have been mapped (Tsai and
Reed, 1998). That the zinc fingers involved
in these different signaling paradigms can
be separated indicates a functional spec-
ification of these structural elements that
merits further scrutiny (see Figures 1B
and 1C for illustration).
Ever since Wolbach and Howe demon-
strated in 1925 that vitamin A deficiency
in rats leads to the development of squa-
mous metaplasia, retinoids and more
recently also rexinoids have been at the
forefront of research into the development
of novel differentiation and apoptosis-
based cancer therapies (for a recent
review, see Altucci et al., 2007). With
the exception of acute promyelocytic
leukemia, where all-trans RA has been an
overwhelming therapeutic success, the
promise of these drugs in cancer therapy
remains to be fulfilled, particularly in solid
tumors. Retinoids and rexinoids have,
however, yielded encouraging results for
acute myeloid leukemia (AML) when
used in combination with other signaling
drugs (Altucci et al., 2005). Furthermore,
the addition of 13-cis RA as maintenance
therapy has significantly improved the
outcome of patients with a high-risk form
of neuroblastoma (Matthay et al., 2009),
andcombinationwith histonedeacetylase
inhibitorsmay further increase therapeutic
efficacy (Hahn et al., 2008).Collectively, the results of these and
other studies strongly suggest that the
poor response of some tumors to reti-
noid/rexinoid-based therapies may be
due at least in part to an imbalance
between positively and negatively acting
RAMs in cancer cells. Interestingly, the
Huang et al. study shows that high
expression of ZNF423 correlates with
good outcomeof neuroblastomapatients,
possibly reflecting enhanced levels of RA
signaling. Consistent with this hypothesis,
the expression of PRAME, which inhibits
RA signaling, has been associated with
poor outcome of neuroblastoma patients.
It will be interesting to investigate whether
the accuracy of prognosis in this disease
can be improved by using both ZNF423
and PRAME as markers. It also remains
to be determined whether expression of
ZNF423 can predict a better response to
RA treatment, possibly even in relapsed
and therapy-resistant disease. One
important finding of the Huang et al. study
is that the introduction of ZNF423 into
RA-resistant neuroblastoma cell lines
restores their differentiation response to
RA, indicating that finding ways to elevate
ZNF423 levels may be therapeutically
useful. The authors point out that DNA
methylation inhibitors have no effect on
ZNF423 expression, but one cannot
exclude that other modifications, perhaps
even PRAME/EZH2-mediated trimethyla-
tion of histone H3 lysine 27, silence this
gene. In this respect, DZNep (3-deazane-
planocin A), a compound that targets the
EZH2-containing polycomb complex for
degradation, may prove to be useful in
restoring some ZNF423 expression and/
or activity.
A potential role for ZNF423 in other
cancers and their sensitivity to RA also
remains tobeexplored.Ahighlyconserved
member of this family, ZNF521, is ex-
pressed (potentially aberrantly) in a
majority of AML (Bond et al., 2008). An
interesting caveat here is that ZNF521
binds the repressivenucleosome remodel-
ing and deacetylase (NuRD) complex and
may in fact constitute one of the growing
number of factors that inhibit RA response
in AML. Although the ZNF423 cDNA used
in the Huang et al. study did not contain
this NuRD interaction domain (NID), an
analysis of genomic and expressed
sequence databases indicates that human
ZNF423 can be expressed as several iso-
forms, one of which possesses the NIDCancer C(Figure 1C). Interestingly, it appears that
the mouse gene can only express the
NID-containing isoform, complicating the
interpretation of the F9 and embryonic
stem cell data in the current study.
However, it is possible that despite pos-
sessing a NuRD-binding motif, ZNF423
doesnotbindNuRDorhaveany repressive
potential in the context of the RAR
complex. With respect to neuroblastoma,
it is worth noting that expression sequence
tags for ZNF423 transcripts that encode
the NID were isolated from neuroblastoma
cells and cerebellum. Therefore, it may be
important to establishprevalenceand rela-
tive ratio of the isoforms possessing or
lacking the NID, as well as activity on all-
trans RA signaling in neuroblastoma cells,
as this may give further insight into the
pathogenesis of this disease, providing
clinicians with a better prognostic tool in
addition to opening newavenues for trans-
lational research.
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